mTOR inhibitor
Original Article Synergistically suppressive effects on colorectal cancer cells by combination of mTOR inhibitor and glycolysis inhibitor, Oxamate
... of mTOR inhibitor on cancer cells glucose meta- bolism are rare ...of mTOR inhibitor in its antitumor effect as an inhibitor of ...
7
Objective Monitoring of mTOR Inhibitor Therapy by Three-Dimensional Facial Analysis
... We describe the first instance of 3DFA assessment of the response of a head and neck lymphatic vascular malforma- tion to mTOR inhibitor therapy. Specifically, using methods that harmoniously assess facial ...
5
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
... Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum ...
11
The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
... kinase inhibitor with an mTOR inhibitor might have complementary growth- inhibitory effects against ...PIM inhibitor AZD1208 and of mTOR by selective mTORC1/2 dual inhibitor ...
18
Case Report Dramatic response to an mTOR inhibitor in a Chinese patient with lung squamous cell carcinoma with an mTOR mutation and PIK3CA amplification: a case report
... in mTOR and PIK3CA amplification accompanied by TP53 P153Rfs*27 and H178Tfs*69 muta- ...tions. mTOR S2215T mutation, TP53 P153R- fs*27 and H178Tfs*69 mutations were verifi- ed by first-generation sequencing ...
5
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
... HDAC inhibitor VPA and the MTOR inhibitor temsirolimus, both at a clinically achievable concentration [19,20], interacted synergistically to inhibit BL cell ...
11
Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
... an mTOR inhibitor induced apoptosis in human cutaneous SCC cell ...the mTOR inhibitor exhibited antiproliferative effects in the HSC-1 cell line after 72 hours of ...phosphorylated mTOR ...
11
In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
... PI3K/mTOR inhibitor GSK2126458 ...caspase inhibitor I [N-benzyloxy- carbonyl-val-ala-asp(O-methyl)-fluoromethylketone; zVAD; ...pancaspase inhibitor] was purchased from Calbiochem (La Jolla, ...
11
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
... Results: A total of 17 children (median age at study inclusion 2.4 years, range 0 – 6; 12 males, 5 females) with TSC who received early mTOR inhibitor therapy were studied. mTOR inhibitor ...
13
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
... prior mTOR inhibitors (2 patients had received temsirolimus and 1 patient had received everolimus), four patients had received prior bevacizumab, and seven patients had received prior ...
12
Deptor: not only a mTOR inhibitor
... Most of the studies investigating Deptor have been pri- marily focused on its role as inhibitor of mTOR kinase activity. Interestingly, the nuclear localization of Deptor in MM cells has been recently ...
9
Possible Prevention of Tuberous Sclerosis Complex Lesions
... the mTOR inhibitor everolimus was shown to be effective in the treatment of subependymal giant cell astrocytomas (a brain tumor) and renal AMLs (kidney tumors) in TSC ...no mTOR inhibitor ...
6
Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
... the mTOR inhibitor temsirolimus when combined with the existing paclitaxel/carboplatin therapy in patients with stages III/IV CCC, whereas GOG0254 is a Phase II clinical study designed to examine the ...
5
Systemic treatment of advanced papillary renal cell carcinoma: Where next?
... Bernard Escudier and colleagues are to be congratulated for successfully recruiting and reporting the RAPTOR study in this edition of EJC (1). This phase 2 trial evaluated the efficacy and safety of the orally ...
6
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
... levels ranged from 3 to 14 ng/mL depending on time after HTX: 1.0 year after HTX, 6–14 ng/mL; 1.0 year after HTX, 4–8 ng/mL; and 2.0 years after HTX, 3–6.5 ng/mL. In patients with significant renal insufficiency, ...
10
Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
... of mTOR inhibitors in children, specifically regard- ing their effect on growth and gonadal function over the ...of mTOR inhibitors in children with TSC [35, 36], however 5-year data from a phase II study ...
14
A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas
... an mTOR inhibitor, uncontrolled brain metasta- ses, a history of hypersensitivity to macrolide antibiot- ics (because of the risk of crossreactions), or grade 3 or 4 ...
9
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
... of mTOR complexes with the catalytic mTOR inhibitor OSI-027 and of the p110α subunit of PI3K with the specific inhibitor BYL- 719 results in efficient suppression of effector pathways and ...
9
MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression
... the mTOR inhibitor rapamycin to investigate the putative link between mTOR signalling and MMP expression in gastric ...of mTOR signalling has been assessed by Western blot for the main ...
5
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models
... PI3K/mTOR inhibitor NVP-BEZ235 robustly blocks this pathway and the combination of dovitinib + NVP-BEZ235 had significantly better anti-tumor and anti-metastatic activity than treatment with single inhibi- ...
16